Hematology and Oncology

No reduction seen in mortality or key morbidities, including CV events, cerebrovascular events, cancer, peripheral fractures, kidney stones

Median drug price markups across centers ranged from 120 to 630 percent

Survey shows many doctors less likely to recommend e-cigarettes for people seeking to quit smoking

Method for assessing occupational pesticide exposure seems not to influence risk estimates for prostate cancer, NHL, Parkinson disease

Systemic inflammatory biomarkers may be useful in the differential diagnosis of primary central nervous system lymphoma, high-grade glioma

Mechanisms of resistance detectable prior to treatment and include hypermethylation of PCR2 targets in embryonic and cancer stem cells

Event-free survival prolonged and percentage of patients with a pathological complete response higher with addition of nivolumab

However, recovery is uneven, particularly among historically marginalized racial and ethnic groups

However, there were no statistically significant changes in rates by race

However, higher risk seen for breakthrough infections and severe outcomes, especially for hematologic malignancies